THOUSAND OAKS, Calif., and COLLEGEVILLE, Pa., June 19, 2003 - Amgen (NASDAQ: AMGN) and Wyeth Pharmaceuticals, a division of Wyeth (NYSE: WYE), today announced that patients in a phase 3 clinical study ...

THOUSAND OAKS, Calif., November 12, 2006 -- Amgen (NASDAQ: AMGN) today announced that Enbrel? (etanercept) is the first biologic with published data to show improvements in multiple measures of ...

An appeals court ruling means biosimilar competition won't affect U.S. Enbrel sales for a long time. Enbrel is a tumor necrosis factor (TNF) inhibitor that earned its first FDA approval all the way ...

WASHINGTON — Colorado is pioneering a new way for states to crack down on prescription drug costs. In a first-in-the-nation move, a state board voted to create a payment limit for a widely prescribed ...

After back-to-back losses in court, Novartis’ generics outfit Sandoz had hoped the U.S. Supreme Court would take up its long shot biosimilars case against Enbrel maker Amgen. But now that effort has ...

Amgen last summer scored a major patent win to defend its blockbuster immunology med Enbrel from impending biosimilar competition. Now, Novartis is challenging that ruling in appeals court, but ...

On Monday, May 17 th, the U.S. Supreme Court decided not to take up Sandoz’s petition for the Court to review previous lower court decisions on the launch of its biosimilar product. This included a ...

Last week, the Federal Circuit denied Sandoz’s petition for an en banc rehearing of its precedential July 1st panel decision upholding two of Immunex’s patents covering Enbrel®. As explained in the ...

Susan Estrich is the Robert Kingsley Professor of Law and Political Science at the University of Southern California Law Center as well as being a syndicated columnist. The U.S. government this week ...

An eight-year-old patent suit over the blockbuster drug Enbrel, which put Seattle’s Immunex Corp. on the map, is over. The winner? Amgen, which bought Immunex six years ago. Back in 1999, the Israel ...